Evidence map›Paper›PMID 40052221›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

YC-4-3, a Novel Glycogen Synthase Kinase 3β Inhibitor, Alleviates the Endoplasmic Reticulum Stress of Macrophages in Primary Immune Thrombocytopenia.

Pengcheng Xu, Lili Ji, Yanxia Zhan, Yang Ou, Xia Shao, Xibing Zhuang, Fanli Hua, Feng Li, Hao Chen, Yong Chu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Pengcheng XuDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Lili JiDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yanxia ZhanDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yang OuDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Xia ShaoCenter for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Xibing ZhuangDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Fanli HuaDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Feng LiDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Hao ChenDepartment of Thoracic Surgery, Zhongshan - Xuhui Hospital, Fudan University, Shanghai, 200031, China.
Yong ChuDepartment of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, 201203, China.
Yunfeng ChengDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.ORCID https://orcid.org/0000-0002-9581-1134

Funding

Doctor Fund of Doctor Fund of QingPu Branch of Zhongshan Hospital Affiliated to Fudan University QYBS2023-03Key Medical Discipline Construction Project of Xuhui District SHXHZDXK202316Key Subject Construction Program of Shanghai Health Administrative Authority ZK2019B30National Natural Science Foundation of China 81870098National Natural Science Foundation of China 82370130National Natural Science Foundation of China 82400150Postdoctoral Fellowship Program of CPSF GZC20230509Program of the Shanghai Academic/Technology Researcher leader 20XD1401000Shanghai Engineering Research Center of Tumor Multi-Target Gene Diagnosis 20DZ2254300Shanghai Municipal Committee of Science and Technology 19431900600
6 · The paper itself

Abstract

Primary immune thrombocytopenia (ITP) is a heterogeneous autoimmune disease, characterized by decreased platelet count and increased risk of hemorrhage, in which macrophages play an important role in the pathogenesis. This study aims to explore the effects of YC-4-3, the patented chemical synthesis of benzothiazepinone compounds (BTZs), a novel GSK-3β inhibitor (GSK-3βi), on macrophages in ITP. The expressions of GSK-3β in monocytes are tested. The effects of GSK-3βi (YC-4-3) on macrophages of ITP patients are examined and validated in passive and active murine models. Signal pathway enrichment analysis is performed. The interaction proteins of endoplasmic reticulum (ER) stress and GSK-3β are explored. The GSK-3β

Indexed as

Endoplasmic Reticulum StressGlycogen Synthase Kinase 3 betaMacrophagesPurpura, Thrombocytopenic, IdiopathicAdultAnimalsDisease Models, AnimalFemaleHumansMaleMiceMice, Inbred C57BLMiddle AgedSignal TransductionGlycogen Synthase Kinase 3 betaendoplasmic reticulum (ER) stressglycogen synthase kinase 3β (GSK‐3β)macrophagesnone‐catalytic ATP‐binding siteprimary immune thrombocytopenia

Identifiers

PMID40052221
PMCPMC12061250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.